Alexandra Passarelli

Dr. Alexandra Passarelli

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2026 in Wellcome Open Research
Verified
Journal Article
Open access
AFArmelle Forrer
Armelle Forrer
HKHenry Kajumbula
Henry Kajumbula
ENEdward O. Nyarko
Edward O. Nyarko
IBImmaculate Barasa
Immaculate Barasa
MOMoses Odhiambo
Moses Odhiambo
NFNicholas Feasey
Nicholas Feasey
Background Healthcare-associated infections (HAIs) significantly contribute to patient morbidity and mortality worldwide, particularly in sub-Saharan Africa (sSA), where prevalence rates range between 6.7% and 28%. HAI are particularly associated with extensive antimicrobial resistance (AMR), which may potentially render HAI untreatable in settings with poor access to Watch and Reserve antibiotics. Methods This observational cohort study, conducted across hospitals in Kenya, Ghana, Malawi, and Uganda, aimed to estimate antimicrobial resistance (AMR) rates in HAIs, describe clinical outcomes, and assess hospital length of stay (LoS) among hospitalized patients with HAIs. Kaplan Meir plots were used to explore the impact of treatment adequacy on survival rate for different HAIs. Mixed-effect logistic regression models were used to assess the impact of drug resistance or treatment inadequacy on odds of survival. Results Of 336 participants enrolled between October 2021 and January 2023, 207 had at least one positive microbiological test, contributing 244 isolates. The highest AMR prevalence was observed in the Enterobacterales family, Staphylococcus aureus , and Acinetobacter spp. of which 85.3% (116/136), 78.6% (11/14) and 72.7% (16/22) exhibited AMR, respectively. Over 80.9% (114/141) of pathogenic isolates were either 3GC-R or MDR and 88.6% of those (101/114) were both MDR and 3GC-R. There was a 16.7% case fatality rate, with inadequate or unknown adequacy of antimicrobial treatment significantly associated with increased odds of death in patients with bloodstream infection, hospital acquired pneumonia or complicated skin and soft tissue infection (OR 2.90, 95% CI 0.99–8.36). Increased odds of death were also associated with hospital stay in an ICU ward (OR 4.70, 95%CI 1.80–12.32) and with increasing years of age (OR 1.01, 95%CI 1.01–1.04). Conclusion The findings highlight the urgent need for local treatment guidelines, improved infection prevention and control measures, and antimicrobial stewardship in sSA to reduce the burden of AMR and improve patient outcomes.

25 May 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
ALAmy W Law
Amy W Law
DMDanielle Mayer
Danielle Mayer
MZMarjan Zakeri
Marjan Zakeri
NYNehir Yapar
Nehir Yapar
APAlexandra Passarelli
Alexandra Passarelli
PMPia D.M. MacDonald
Pia D.M. MacDonald
Background/Objectives: Respiratory syncytial virus (RSV) is the leading cause of infant hospitalizations in the United States. Prevention strategies are recommended to mitigate severe RSV outcomes. In addition to identifying potential coverage gaps, preventative administration timing is important for estimating product effectiveness. This study characterized administration timing of maternal and infant immunization against RSV across the United States during the 2024–2025 RSV season. Methods: A retrospective cross-sectional study was conducted using administrative claims of a commercially insured population from Kythera Labs. Pregnant individuals who received RSVpreF vaccine and infants who received nirsevimab were included. The seasonal cohort included infants born during the RSV season, while infants born from April to September were considered as the catch-up cohort. Baseline characteristics and calendar month and age at immunization (gestational age for RSVpreF) were evaluated. Results: Overall, 37,686 (71.9%) of maternal vaccinations were administered at 32–34 gestational weeks and 92.7% of all vaccinations occurred ≥14 days before delivery. Among infants who received nirsevimab, 34.8% of the seasonal cohort were immunized within 1 week of birth and 33.4% of the catch-up cohort were immunized in October 2024. Conclusions: Most maternal RSVpreF vaccinations occurred early in the recommended eligible gestational age window, while only approximately one-third of infants received nirsevimab during the first week of life or at the beginning of the RSV season. These findings highlight the importance of timely administration of RSV preventives. They further demonstrate that immunization timing should be incorporated into evaluation of the effectiveness and population level impact of RSV prevention programs.